Research graph
References from Brentuximab Vedotin‐Induced Rash Sparing CD30‐Positive Mycosis Fungoides Lesions. Local targets link to admitted publications; unresolved targets remain external evidence.
Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma
10.1007/s11899-020-00561-w · 2020 · External reference
S2k‐Guidelines ‐ Cutaneous Lymphomas (ICD10 C82 ‐ C86): Update 2021
2022 · External reference
Brentuximab Vedotin or Physician's Choice in CD30‐positive Cutaneous T‐Cell Lymphoma (ALCANZA): An International, Open‐Label, Randomised, Phase 3, Multicentre Trial
10.1016/s0140-6736(17)31266-7 · 2017 · External reference
Results of a Phase II Trial of Brentuximab Vedotin for CD30+ Cutaneous T‐Cell Lymphoma and Lymphomatoid Papulosis
10.1200/jco.2014.60.3787 · 2015 · External reference
Histopathologic and Clinical Characterization of Brentuximab Vedotin‐Associated Rash
10.1097/pas.0000000000002268 · 2024 · External reference
